Coronavirus Update: Oxford Racing Ahead With 8,000 Vaccinated In Phase III Trial

Plus: Eisai Joins RE-MAP Cap Study

Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.  

Covid19_Carpark
Oxford, UK: The trials led by the university's Jenner Institute have already vaccinated 8,000 subjects

The University of Oxford team developing a coronavirus vaccine with AstraZeneca PLC is well ahead in the race to conduct late-stage trials, with 8,000 volunteers already dosed in its Phase III study.

This puts it far in advance of other frontrunners such as Moderna Inc. and Pfizer Inc., who are...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip